Recruiting Obesity Studies in Phoenix
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will e...
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB)....
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight ma...
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforg...
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweig...
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or ov...
Aleniglipron Phase 2 Body Composition Study
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to alenigli...
About Obesity Clinical Trials in Phoenix
Obesity is a complex chronic disease involving an excessive amount of body fat that increases the risk of other diseases and health problems. It affects over 650 million adults worldwide. Treatment approaches include lifestyle modifications, medications (GLP-1 agonists), and bariatric surgery.
There are currently 7 obesity clinical trials recruiting participants in Phoenix, AZ. These studies are seeking a combined 21,831 participants. Research is being sponsored by Eli Lilly and Company, Currax Pharmaceuticals, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.
Obesity Clinical Trials in Phoenix — FAQ
Are there obesity clinical trials in Phoenix?
Yes, there are 7 obesity clinical trials currently recruiting in Phoenix, AZ. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Phoenix?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.
Are clinical trials in Phoenix free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.
What obesity treatments are being tested?
The 7 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for obesity.
Data updated March 2, 2026 from ClinicalTrials.gov